Evidence map›Paper›PMID 39861149›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Development of a Hydrocortisone Orodispersible Thin Film Containing Its Succinate Prodrug.

Clément Boisseillier, Lucas Demange-Labriet, Dulanjalee Kariyawasam, Pauline Marchadour, Anne-Sophie Fauqueur, Maxime Annereau, Lucas Denis, Camille Cotteret, Salvatore Cisternino, Arnaud Schweitzer-Chaput

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Clément BoisseillierService Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, F-75015 Paris, France.
Lucas Demange-LabrietService Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, F-75015 Paris, France.ORCID 0009-0002-2687-231X
Dulanjalee KariyawasamService d'Endocrinologie, Diabétologie, Gynécologie Pédiatriques, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, F-75015 Paris, France.ORCID 0000-0002-3870-202X
Pauline MarchadourService Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, F-75015 Paris, France.
Anne-Sophie FauqueurService Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, F-75015 Paris, France.
Maxime AnnereauService Pharmacie, Institut Gustave Roussy, F-94800 Villejuif, France.ORCID 0000-0001-9594-2516
Lucas DenisService Pharmacie, Institut Gustave Roussy, F-94800 Villejuif, France.
Camille CotteretService Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, F-75015 Paris, France.
Salvatore CisterninoService Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, F-75015 Paris, France.
Arnaud Schweitzer-ChaputService Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, F-75015 Paris, France.ORCID 0000-0002-3558-8997

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Orodispersible thin film (ODF) is an innovative dosage form that allows for adjustable dosing and improved patient compliance. It is administered by mouth, where it dissolves, making it suitable for children.

objectivesThe aim of the study was to develop and characterize an optimal ODF formulation containing equivalent hydrocortisone at 0.5 mg/cm

resultsWhen optimized, ODF is thin, flexible, and transparent, making it suitable for production in hospital pharmacies using standard equipment. In contrast to the water-insoluble hydrocortisone, the HMS-loaded cast gel successfully satisfied the tests, including content uniformity. Disintegration appeared acceptable as compared to the commercial grade ondansetron ODF (Setofilm

conclusionThe ODF formulated with the water-soluble hydrocortisone prodrug HMS allows accurate drug level to be achieved, thus opening up new opportunities for use in pediatric patients.

Indexed as

21-hydroxylase deficiencyadrenal hyperplasiadrug compoundinghydrocortisonepediatricspersonalized medicinepharmacy service

Identifiers

PMID39861149
PMCPMC11768698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.